Why So Many Biopharma M&A Transactions Start Out as Aspirational Licensing Deals скачать в хорошем качестве

Why So Many Biopharma M&A Transactions Start Out as Aspirational Licensing Deals

On the heels of the publication of Locust Walk’s latest white paper “Bought Not Sold” we are joined by a great panel of experts to help us unpack how M&A transactions evolve in the biopharma space. Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand: the majority of acquirers only became interested in pursuing an acquisition after they had a chance to view a target company’s detailed data and financials in the context of licensing talks. During the webinar, we will explore: Why are most biopharma’s bought, not sold and why you should let acquirers drive the process. How many suitors you should have and how to fill your dance card and how an advisor can assist in navigating this process. The typical milestone events and timelines for a successful biopharma acquisition and when to time your outreach relative to data availability and when to pivot. Panelists: Geoff Meyerson, CEO, Locust Walk (Moderator) Tony Gibney, CFO and CBO, Fog Pharma Naomi Leslie, Managing Director, Goldman Sachs Andy Meyerson, Managing Director, Head of North American Strategic Transactions, Locust Walk